Диклоберл

Quick links to important sections

Диклоберл

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Диклоберл

What is Диклоберл?

Property Description
Active ingredient Diclofenac (as sodium or acid salt)
Form Tablets, capsules, suppositories, injection solution, topical gels
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of pain, inflammation, and fever
Origin Synthetic (Phenylacetic acid derivative)

What Type of Medicine is Диклоберл?

Диклоберл (Dicloberl) is a widely used, prescription-only medication whose core therapeutic agent is Diclofenac. It is officially categorized as a Non-Steroidal Anti-Inflammatory Drug (NSAID), a class of synthetic compounds known to possess potent anti-inflammatory and analgesic properties.

Diclofenac is structurally identified as a phenylacetic acid derivative. Its classification as an NSAID confirms its triple therapeutic function: acting as an anti-inflammatory, an analgesic (pain reliever), and an antipyretic (fever reducer). This means the medicine is specifically designed to address symptoms driven by underlying inflammatory processes, such as chronic stiffness or acute musculoskeletal discomfort.

Composition and Available Pharmaceutical Forms

The essential component of the medicine is Diclofenac, formulated as its sodium or acid salt, combined with pharmaceutical excipients. Диклоберл is a single-ingredient product recognized for offering comprehensive forms for systemic and localized relief, differentiating it from single-form medications.

Its preparations include oral dosage forms, such as tablets and extended-release capsules, as well as suppositories and solutions in ampoules for parenteral (injection) administration. This wide range of forms ensures the active substance can be delivered effectively via the most appropriate route, offering flexibility in patient care for conditions involving pain and inflammation.

General Purpose and How Diclofenac Works (High-Level)

The general purpose of Диклоберл is to provide multifaceted symptomatic relief by combining its analgesic, anti-inflammatory, and antipyretic actions. It achieves this by focusing directly on the body's inflammatory response system.

The high-level principle involves the inhibition of prostaglandin synthesis. These prostaglandins are the chemical messengers that trigger and sustain the sensations of pain, swelling, and fever. By blocking the enzymes (Cyclooxygenase, or COX) responsible for generating these substances, the medicine effectively reduces the biological processes that lead to discomfort.

What side effects are possible with Диклоберл?

Possible Side Effects and Safety Information

Диклоберл (Diclofenac), a systemic nonsteroidal anti-inflammatory drug (NSAID), carries a well-documented safety profile that includes warnings regarding serious and clinically significant adverse reactions, primarily affecting the cardiovascular and gastrointestinal systems. Regulatory agencies emphasize that these risks are often dose- and duration-dependent.

Adverse Reaction Category Key Serious Risks (Regulatory Warning)
Cardiovascular System Increased risk of serious thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may increase with higher doses and longer duration of use.
Gastrointestinal System Increased risk of serious events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal and may occur without warning symptoms.
Hepatobiliary System Risk of elevated liver enzymes and, in rare cases, severe hepatic injury (liver damage) including liver failure.

Commonly Reported Side Effects (e.g., in clinical trials/surveillance) include gastrointestinal complaints such as nausea, diarrhea, indigestion, stomach pain, and flatulence. Headache, dizziness, and rash are also frequently reported.

Important Safety Restrictions The drug is contraindicated for systemic use in patients with established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease. Caution is advised for patients with significant risk factors (e.g., hypertension, diabetes, smoking). All patients are advised to use the lowest effective dose for the shortest duration necessary to mitigate potential risks. Additionally, serious skin reactions and hypersensitivity events (including anaphylaxis) have been reported, sometimes with fatal outcomes, requiring immediate discontinuation at the first sign of a rash or allergic reaction.

Overdose and Emergency Response

Overdose: When to Seek Urgent Medical Help

Overdose with diclofenac (the active ingredient in Диклоберл) is characterized primarily by serious gastrointestinal and systemic effects. Urgent medical attention is required in the event of suspected overdose or the onset of severe adverse reactions.

Documented Overdose Manifestations

Acute overdose presentations typically include gastrointestinal disturbances such as nausea, vomiting, epigastric pain, and gastrointestinal bleeding. Less commonly, effects such as irritability, renal dysfunction, hepatic dysfunction (hepatitis), blood dyscrasias, or acute hypersensitivity reactions like bronchospasm and anaphylaxis may occur.

Overdose risk factors include exposure to high doses, which is associated with an increased risk of severe adverse events, including gastrointestinal bleeding, ulceration, or perforation. Elderly patients are noted to be at a higher risk for serious gastrointestinal complications.

Required Emergency Actions

As there is no known specific antidote for diclofenac, treatment is purely symptomatic and supportive. Immediate medical assistance is necessary if any of the following occur:

  • Signs of gastrointestinal bleeding or ulceration.
  • The first appearance of a skin rash, mucosal lesions, or any other signs indicative of a severe hypersensitivity reaction.
  • Accidental ingestion of topical formulations resulting in significant systemic adverse effects.

In all cases of suspected overdose, prompt consultation with emergency medical services is critical.

Therapeutic Uses of Диклоберл

What Диклоберл Treats: Main Uses and Benefits

Диклоберл (Diclofenac) is used in situations involving certain distressing symptoms to provide supportive symptomatic relief, a function that is generally considered relevant in therapeutic practice. It is relevant in contexts marked by increased discomfort and is commonly used to help with symptoms that interfere with daily functioning.

Symptom Management and Therapeutic Domains

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns. It is commonly used to help with conditions characterized by periods of heightened symptoms, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis, as well as sudden events like acute pain from injuries, migraine attacks, and the discomfort of primary dysmenorrhea (menstrual cramps). It also plays a role in managing symptoms related to systemic imbalance by assisting with the reduction of fever.

The application is aimed at providing supportive relief when symptoms create noticeable physiological strain, which supports patients during difficult episodes by easing distress.

By addressing symptom clusters that may become intense, the medication supports general comfort during symptomatic periods and may assist with maintaining functional stability during symptomatic phases.

Quick Fact: Relief for Pain and Inflammation
This medication is primarily relevant for easing symptoms related to inflammatory or irritative states where physical discomfort and swelling are pronounced.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Диклоберл?

The eligibility for using Диклоберл (Diclofenac) is strictly defined by regulatory guidelines based on a patient's pre-existing conditions and physiological status.

Contraindications (Must Not Use)

The medicine is formally contraindicated and must not be used by patients with:

  • A known hypersensitivity to diclofenac, aspirin, or any other NSAID.
  • An active gastric or intestinal ulceration, bleeding, or perforation.
  • Severe renal or hepatic impairment.
  • Established Congestive Heart Failure (NYHA Class II-IV), Ischaemic Heart Disease, Peripheral Arterial Disease, or Cerebrovascular Disease.
  • Use is prohibited in the third trimester of pregnancy (at or after 30 weeks' gestation).

Age and Conditional Use

Population Group Official Eligibility Status
Children under 12 Safety and efficacy not established for most systemic forms.
Elderly Patients Use requires particular caution due to increased susceptibility to adverse reactions.
20–30 Weeks' Pregnancy Use is restricted to the lowest effective dose for the shortest duration.
Lactating Women Passes into breast milk in small amounts; use is generally considered acceptable but requires clinical consideration.

For patients with mild to moderate renal or hepatic impairment, use should proceed with caution and clinical monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Diclofenac (Диклоберл) details specific interaction patterns concerning co-administered substances, focusing strictly on pharmacokinetic and pharmacodynamic outcomes as documented in prescribing labels.

Pharmacokinetic Interactions

Co-administration with CYP2C9 inhibitors, such as Voriconazole, is officially documented to increase Diclofenac's plasma concentration ( C max and AUC). This pharmacokinetic inhibition affects the elimination of Diclofenac.

Pharmacodynamic Interactions and Restrictions

The most significant documented pharmacodynamic interactions involve additive risk and counteraction of efficacy.

Interaction Type Interacting Medicines Official Outcome
Reinforced Risk Other systemic NSAIDs, Aspirin, Anticoagulants, SSRIs, Corticosteroids Increased risk of serious gastrointestinal bleeding and adverse events.
Counteraction ACE Inhibitors, ARBs, Diuretics May diminish the antihypertensive or diuretic effect; increased risk of renal function impairment documented.

Use of Diclofenac is contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery and with a known history of allergic reactions to other NSAIDs. Alcohol consumption is formally restricted due to the documented increase in gastrointestinal bleeding risk. Certain rapid-release oral formulations are subject to timing rules, requiring administration on an empty stomach to prevent reduced effectiveness.

Mechanism of Action

Enzyme Target and Primary Cascade Blockade

The pharmacological action of Диклоберл (Diclofenac) is achieved primarily through the competitive inhibition of Cyclooxygenase (COX) enzymes, specifically targeting both COX-1 and COX-2. By blocking the COX enzymes, the drug prevents the synthesis of prostaglandins—powerful mediators that sensitize nerves and escalate inflammatory responses. This suppression of mediator production leads directly to the physiological effect of dampening the inflammatory cascade and lowering the threshold for peripheral nociceptor activation.


Multimodal Action and Sustained Local Modulation

This second mechanistic domain involves non-COX-dependent modulation and the drug's persistence in target tissues. Diclofenac influences nociceptive signaling by engaging pathways like the Nitric Oxide/cGMP system, which alters the threshold for peripheral nerve activation. Furthermore, the drug tends to accumulate in sites like the synovial fluid, sustaining the concentration needed to maintain inhibition and facilitate prolonged enzyme-substrate interaction dynamics within targeted peripheral pathways.

Dosage and Administration Information

The administration of Diclofenac, the active ingredient in Диклоберл, is governed by protocols that define the route, quantity, frequency, and handling of its various pharmaceutical forms. The medicine is utilized for systemic delivery via oral intake (tablets, capsules, solutions), rectal administration (suppositories), and intravenous (IV) injection, alongside topical preparations for localized use.

A central principle across all systemic forms is the use of the lowest effective dose for the shortest duration necessary. For adult patients, the total systemic daily dose generally ranges from 75 mg to 150 mg, which should not exceed the 150 mg daily maximum for most uses. This amount is typically administered in two or three divided doses over the day to maintain a consistent therapeutic schedule.

Specific instructions govern the handling of different formulations. Extended-release tablets, for example, are required to be swallowed whole and must not be crushed, chewed, or divided to ensure the active substance is released as intended. The timing of intake is often formulation-dependent: some tablets are recommended to be taken with or after food, while oral solutions for acute episodes may be taken on an empty stomach. Furthermore, specific procedural conditions apply to the older adult population, where guidance necessitates starting at the lowest viable dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Диклоберл


Evidence for Use in Osteoarthritis and Rheumatoid Arthritis

Research has explored Diclofenac in the context of conditions associated with acute or disruptive episodes, such as Osteoarthritis (OA) and Rheumatoid Arthritis (RA). Researchers utilized Randomized Controlled Trials (RCTs), comparing the medicine to inactive substances (placebo) and to active compounds (other anti-inflammatory drugs). These studies were applied in populations of adults and older adults experiencing joint discomfort and were designed to explore how symptoms change over time.

Studies monitored outcomes related to physical discomfort using patient-reported scales, such as the WOMAC Index, to measure pain severity and daily functioning (or activity level). The available evidence includes data from trials lasting up to intermediate periods for measured outcomes, and some findings describe patterns observed in these short-term studies, especially concerning joint-specific OA. Research highlights that follow-up durations for many clinical trials were limited, meaning there is insufficient information for long-term outcomes based solely on high-certainty RCTs.


Evidence for Use in Ankylosing Spondylitis

For research evaluating Ankylosing Spondylitis (AS), a condition marked by functional limitations and systemic imbalance, research has focused on different approaches. Studies have explored symptom intensity and variability using specific disease activity indices, such as the BASDAI and ASDAS, along with measures of physical function. Long-term research has also examined structural changes in the spine using measures like the mSASSS over periods up to two years.

What remains uncertain is the long-term effect of continuous versus on-demand dosing on structural outcomes like radiographic progression, as findings were mixed across different studies that examined this factor over extended periods.


Evidence for Use in Acute Pain and Symptomatic Relief

The research relevant to exploring acute or disruptive episodes of pain (such as pain following a minor procedure or injury) was conducted using controlled, single-dose RCTs. These trials were applied in research contexts involving fluctuating or unstable symptoms in adult populations. Studies monitored outcomes describing episodic changes, specifically focusing on the time to reported change. These results apply only to the populations studied and only to the study of short-term, acute symptoms.


What is Still Uncertain about the Evidence

Evidence highlights what is known—and what is still uncertain—about Diclofenac. Research data for subgroup findings are uncertain for specific populations, such as younger patients or those with complex comorbidities. Additionally, while different formulations (oral, topical, injectable) were studied, comparative evidence is lacking in certain scenarios to define the exact differences in long-term patient experience between these forms.

Frequently Asked Questions (FAQ)

Common questions about Диклоберл (FAQ)


Q: How quickly does Диклоберл start to work for pain?

A: Official information indicates that for many patients, the onset of action for Diclofenac tablets or capsules is observed within 20 to 30 minutes. Other forms, such as suppositories, may take a few hours to have their effect.


Q: How long does the effect of one dose of Диклоберл usually last?

A: The reported duration of effect for a single dose of Diclofenac is approximately 15 hours, according to official patient information. This scheduling is why the medicine is often taken in divided doses throughout the day.


Q: Is it safe to take Диклоберл if I have kidney issues?

A: According to regulatory documents, severe renal (kidney) impairment is a formal contraindication for use. For patients with mild or moderate kidney issues, caution is advised, and close clinical monitoring of kidney function is often necessary due to the documented risk of impairment.


Q: Can Диклоберл affect liver enzyme tests?

A: Yes, official safety information mentions a risk of elevated liver enzymes and, in rare instances, severe liver damage (hepatic injury). Regulatory advice suggests that liver function should be monitored regularly, especially during long-term use.


Q: Is Диклоберл generally more effective for inflammatory pain than mechanical pain?

A: Diclofenac is primarily defined by its mechanism of action as an anti-inflammatory drug, which involves inhibiting chemical messengers (prostaglandins) that trigger inflammation. Research has explored its use in various pain models, including those driven by inflammatory processes.


Q: What is the typical timeframe for seeing the full benefits of Диклоберл?

A: For chronic conditions like arthritis, the full benefits of the medicine may not be immediate. Clinical trials have measured outcomes over intermediate periods, suggesting it may take several days or longer to experience the full symptomatic effect.


Q: Does the research suggest Диклоберл is better for certain types of arthritis?

A: Diclofenac is formally indicated for the management of symptoms associated with both Osteoarthritis (OA) and Rheumatoid Arthritis (RA). Regulatory texts define appropriate use for both conditions but generally avoid making comparative claims of superiority.


Q: Does the effectiveness of Диклоберл decrease over time?

A: Official guidance for chronic use emphasizes the importance of a periodic re-evaluation of the need for the medicine. Regulatory documents focus primarily on the risk profile, which warns that the dose- and duration-dependent risks for serious side effects may increase over time.


Q: Does taking Диклоберл for a long time change how it works?

A: Regulatory documents primarily focus on the risk profile associated with long-term use. They warn that the dose- and duration-dependent risks for serious adverse events (affecting the heart, blood vessels, and digestive system) may increase over time.


Q: Can Диклоберл be used for tension headaches?

A: Diclofenac is officially indicated for the relief of mild-to-moderate pain and specific acute pain episodes. Certain formulations are specifically indicated for the relief of migraine headache, but general use for tension headache may not be explicitly listed in all official regulatory indications.


Q: Is there a maximum number of days Диклоберл can be used?

A: Regulatory agencies strongly emphasize using the lowest effective dose for the shortest duration possible to reduce risk. While acute use may have specific short-term limits, chronic conditions require ongoing clinical re-evaluation rather than continuous use.


Q: What if I take Диклоберл and feel nauseous afterwards?

A: Nausea is listed in official documents as a common side effect associated with Diclofenac use. If nausea, vomiting, stomach pain, or other digestive symptoms become severe or concerning, official guidance advises immediate contact with a healthcare provider.


Q: Are there any foods or drinks that should be avoided when using Диклоберл?

A: Official information formally restricts alcohol consumption due to the documented risk of increased gastrointestinal bleeding. Additionally, some oral formulations have specific rules regarding intake in relation to food.


Q: Can older adults use Диклоберл safely?

A: Regulatory guidance states that use in older adults requires particular caution. This is because older patients have an increased susceptibility to adverse reactions, and treatment is usually started at the lowest possible dose.


Q: Is there a risk of dependence or addiction with Диклоберл?

A: No, Diclofenac is categorized as a Non-Steroidal Anti-Inflammatory Drug (NSAID). According to official patient information, it is not listed as a controlled substance and does not carry a known risk of dependence or addiction.


Q: Why do some people need to take another medicine along with Диклоберл?

A: For patients considered at high risk of digestive system issues, official practice guidelines may suggest co-administration with a gastro-protective agent. This type of medicine helps mitigate the increased risk of stomach ulceration and bleeding associated with NSAID use.


Q: What are the signs of an allergic reaction to Диклоберл?

A: Official warnings describe the risk of serious allergic and hypersensitivity events, including anaphylaxis. Symptoms requiring immediate discontinuation include a rash, blistering, swelling of the face, tongue, or throat, and difficulty breathing.


Q: Is it okay to take another painkiller if Диклоберл doesn't relieve the pain?

A: Official patient information notes that co-administration with Paracetamol (Acetaminophen) is generally permitted. However, it is strongly advised not to combine it with other NSAIDs like Ibuprofen or Naproxen due to a significantly increased risk of side effects.


Q: Why does the packaging for Диклоберл have strong warnings?

A: Regulatory agencies mandate prominent warnings (often called 'Boxed Warnings' in the US) on the packaging of systemic Diclofenac. This is to highlight the serious and potentially fatal risks of cardiovascular thrombotic events (such as heart attack or stroke) and gastrointestinal bleeding and ulceration.


Q: Is the suppositories form of Диклоберл absorbed faster than the tablets?

A: Official pharmacokinetic data indicates that the rate and extent of absorption can differ between formulations. Patient information generally notes that the suppository form typically takes a few hours to start working, whereas oral forms are often faster.


Q: Can Диклоберл be used for pain after dental work?

A: Diclofenac is formally indicated for the relief of acute pain and pain following procedures. Its use in managing pain after dental work falls under the general scope of acute symptomatic relief, based on official indications.


Q: Does Диклоберл interfere with birth control pills?

A: Official patient information generally states that Diclofenac will not affect the effectiveness of most hormonal contraceptives, including combined and progestogen-only pills. Official documentation should always be consulted for specific interaction concerns.


Q: What does the research say about Диклоберл use in sports injuries?

A: Systemic Diclofenac is formally indicated for the management of acute episodes of pain and inflammation, which includes symptoms following physical trauma or injury. Topical forms are often specifically indicated for localized musculoskeletal injuries.


Q: Is Диклоберл suitable for children?

A: For most systemic forms, the safety and efficacy of Diclofenac have not been established for children under 12 years of age. Use in all pediatric populations, if considered, requires professional determination and close clinical monitoring.


Q: Can Диклоберл affect my eyes or vision?

A: Official safety documents list blurred vision and other visual disturbances as less common or rare side effects for systemic use. If any changes in vision are noted, immediate medical evaluation is generally advised.


Q: Are there any specific lifestyle changes recommended when taking Диклоберл?

A: While there are no broad lifestyle restrictions beyond alcohol, regulatory documents advise careful consideration for patients with cardiovascular risk factors such as hypertension, diabetes, or smoking, as these factors are relevant to the drug's safety profile.


Q: Is Диклоберл related to aspirin?

A: Yes, Diclofenac is classified in the same drug class as aspirin: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Official contraindications prohibit its use in patients with a known hypersensitivity to aspirin or any other NSAID.


Q: Do research trials show different outcomes for men and women using Диклоберл?

A: Official documents often note that there is insufficient information or uncertainty regarding subgroup findings for specific populations. Some research has explored gender differences in how side effects, such as gastrointestinal risk, may manifest.


Q: Is the long-term use of Диклоберл monitored differently than short-term use?

A: Yes, regulatory guidance requires that long-term use includes periodic re-evaluation of the need for the medicine. This also involves close monitoring of lab tests, specifically renal (kidney) and hepatic (liver) function, due to the increased risk of serious adverse events.

How should Диклоберл be stored and disposed of?

The storage and disposal of Diclofenac (Диклоберл) must adhere strictly to the conditions specified in official regulatory labeling to ensure product quality and safety.

Storage Requirements

Condition Requirement
Temperature Store most forms at controlled room temperature (20 C to 25 C), or below 25 C for injection solutions. The product must be kept from freezing.
Protection Keep the medicine in its original container and protect from light (especially injections), moisture, and excessive heat.
Child Safety Store the medication out of the sight and reach of children and pets to prevent accidental exposure.
Stability The product must not be used after the expiration date printed on the packaging.

Disposal Instructions

Any unused or expired Dicloberl must be disposed of according to local regulations for pharmaceutical waste. The official instruction is generally to avoid disposal via household waste or wastewater. Specific forms, such as transdermal patches, must be folded over (sticky sides together) before being discarded to minimize exposure risk.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Диклоберл found in:

A-Z Index: